



## **Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017**

November 9, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2017-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced it will host a live conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2017 to report its third quarter 2017 financial results and provide a corporate update.

To access the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) at least five minutes prior to the start time and refer to conference ID 3890769. An audio webcast of the call will also be available on the Investors & Media section of the Company's website, [www.elevenbio.com](http://www.elevenbio.com). An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

### **About Eleven Biotherapeutics**

Eleven Biotherapeutics, Inc. is a late-stage, clinical oncology company advancing novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. Eleven's lead TPT, Vicinium, is currently in a Phase 3 trial in non-muscle Invasive bladder cancer, with topline three-month data expected in mid-2018. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistant mechanisms. Additionally, the Company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information, please refer to the Company's website at [www.elevenbio.com](http://www.elevenbio.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171109006552/en/>

Source: Eleven Biotherapeutics, Inc.

Stern Investor Relations, Inc.  
Michael Schaffzin, 212-362-1200  
[michael@sternir.com](mailto:michael@sternir.com)